VERA Stock Cash Flow Statements

Vera Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Vera Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31

cash flows from operating activities
net income	-76,531,000	-51,694,000	-43,425,000	-46,632,000	-33,708,000	-28,383,000	-25,655,000	-20,104,000	-20,162,000	-30,069,000	-32,439,000	-24,679,000	-14,853,000	-17,085,000	-16,847,000	-7,611,000	-3,437,000	-4,714,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	119,000	85,000	55,000	24,000
accretion of discount and amortization of premium on debt securities
accretion of loan exit fee and amortization of loan costs	156,000	221,000	217,000	207,000
reduction in the carrying amount of operating lease right-of-use assets	444,000	457,000	548,000	496,000	503,000	517,000	532,000	549,000	564,000	579,000	595,000	561,000	551,000	564,000
stock-based compensation	9,472,000	7,744,000	6,217,000	5,588,000	4,873,000	4,124,000	3,221,000	2,923,000	2,682,000	2,667,000	2,748,000	2,452,000	2,025,000	1,662,000	962,000	933,000	713,000	404,000
payment of vt-109 license fee	50,000	750,000
changes in operating assets and liabilities:
prepaid expense and other current assets	1,714,000	-5,876,000	496,000	-1,843,000	2,720,000	-392,000	809,000	-2,087,000	-2,298,000	3,749,000	-482,000	-154,000			706,000	632,000	-3,517,000	-127,000
other assets	141,000	17,000	9,000	320,000	13,000	9,000	-1,000	-4,000	-299,000	-5,000	-13,000	-66,000	-303,000	271,000
accounts payable	3,895,000	1,597,000	3,063,000	-62,000	-545,000	-5,909,000	-1,182,000	-980,000	7,954,000	-6,665,000	4,979,000	-72,000	-244,000	5,943,000	420,000	-759,000	1,012,000	-198,000
accrued and other liabilities	8,101,000	-4,782,000	-3,767,000
operating lease liabilities	-469,000	-394,000	-529,000	-618,000	-623,000	-637,000	-649,000	-651,000	-665,000	-680,000	-693,000	-647,000	-636,000	-626,000
net cash from operating activities	-54,798,000	-54,406,000	-39,182,000	-36,885,000	-24,782,000	-33,830,000	-25,144,000	-22,973,000	-17,772,000	-26,292,000	-21,162,000	-18,420,000	-19,033,000	-8,981,000	-6,438,000	-5,484,000	-7,665,000	-4,121,000
capex	-208,000	-187,000	-645,000	-238,000	0	0	0	0	0	0	0	-38,000	-6,000	-18,000	0	0	0	0
free cash flows	-55,006,000	-54,593,000	-39,827,000	-37,123,000	-24,782,000	-33,830,000	-25,144,000	-22,973,000	-17,772,000	-26,292,000	-21,162,000	-18,458,000	-19,039,000	-8,999,000	-6,438,000	-5,484,000	-7,665,000	-4,121,000
cash flows from investing activities
purchase of property and equipment	-208,000	-187,000	-645,000	-238,000							0	-38,000	-6,000	-18,000
purchase of marketable securities	-97,259,000	-89,992,000	-294,015,000	-72,945,000	-81,088,000	-254,967,000	-53,200,000	-28,672,000	-108,849,000	-34,209,000	-10,563,000	-40,403,000	-58,087,000	-39,437,000
proceeds from maturities of marketable securities	126,061,000	106,246,000	73,277,000	111,500,000	58,500,000	31,681,000	71,819,000	44,900,000	22,400,000	36,900,000	24,000,000	38,001,000
proceeds from sale of marketable securities			0	0	0	4,000,000	0	0	0	9,543,000
net cash from investing activities	28,544,000	15,317,000	-221,383,000	38,317,000	-22,677,000	-219,286,000	18,556,000	16,228,000	-86,449,000	12,234,000	13,437,000	-2,440,000	-42,094,000	-39,455,000	-5,000,000	0
cash flows from financing activities
proceeds from exercise of stock options and employee stock purchase plan	464,000	1,533,000	2,311,000	752,000	3,439,000	6,911,000	87,000	297,000	432,000	240,000	827,000	975,000	47,000	234,000
proceeds from refinancing under loan and security agreement
payment of deferred issuance costs related to unfunded loan commitments
proceeds from short swing settlement			0	0	0	37,000
proceeds from issuance of common stock in follow-on offering				0	0	287,500,000
payment of issuance costs and underwriting fees related to follow-on offering
net cash from financing activities	20,285,000	1,533,000	325,955,000	739,000	3,439,000	276,540,000	24,828,000	297,000	432,000	107,984,000	20,709,000	908,000	48,000	80,268,000	4,921,000	0	48,989,000	-28,000
net decrease in cash and cash equivalents				2,171,000
cash and cash equivalents, beginning of period	0	92,646,000		0
cash and cash equivalents, end of period	-5,969,000	55,090,000		2,171,000
supplemental disclosure of cash flow information
cash paid for interest expense	1,657,000	1,581,000	1,662,000	1,736,000	1,734,000	1,520,000				3,253,000				104,000
accretion of discount and amortization of premium on purchase of debt securities		-2,531,000	-2,066,000	-2,431,000
payment of issuance costs and underwriting fees related to follow-on offerings
net increase in cash and cash equivalents		-37,556,000
receivable on exercise of stock options						13,000
proceeds from borrowings, net of costs
repurchase of common stock			0
proceeds from issuance of common stock in follow-on offerings
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
payment of costs and underwriting discounts and commissions related to follow-on offering				0	0	-17,908,000	0	0	0	-7,256,000	67,000
cash paid for operating leases				815,000	764,000	764,000	762,000	746,000	746,000	746,000	743,000	680,000	655,000	656,000
addition to right-of-use assets obtained from operating lease liabilities
accrued and other current liabilities					4,579,000	-1,690,000	-1,054,000	-1,192,000	-4,606,000	4,637,000	4,745,000	474,000	-2,406,000	4,223,000	3,217,000	1,023,000	84,000	1,069,000
depreciation, amortization and accretion						-1,469,000	-1,167,000	-1,442,000	-971,000	-506,000	-597,000	-152,000	-106,000	9,000	32,000	59,000	50,000	35,000
net increase in cash and cash equivalents and restricted cash						23,424,000				93,926,000	12,984,000	-19,952,000	-61,079,000	31,832,000	-6,517,000	-5,484,000	42,120,000	-4,149,000
cash, cash equivalents and restricted cash, beginning of period						45,681,000		0	0	43,752,000		0	0	79,967,000		0	0	53,997,000
cash, cash equivalents and restricted cash, end of period						69,105,000		-6,448,000	-103,789,000	137,678,000		-19,952,000	-61,079,000	111,799,000		-5,484,000	42,120,000	49,848,000
reconciliation of cash and cash equivalents and restricted cash to the balance sheets
cash and cash equivalents						69,105,000	18,240,000	-6,448,000	-103,496,000	137,385,000	12,984,000	-19,952,000	-61,079,000	111,506,000	-6,517,000	-5,434,000	42,120,000	49,505,000
restricted cash										293,000	0	0	0	293,000	0	-50,000	0	343,000
total cash and cash equivalents and restricted cash						69,105,000	18,240,000	-6,448,000	-103,789,000	137,678,000	12,984,000	-19,952,000	-61,079,000	111,799,000		-5,484,000	42,120,000	49,848,000
issuance of class a common stock for licensing payment, net of costs
change in fair value of non-marketable equity securities							2,000	15,000	29,000	1,000	64,000	202,000			247,000	364,000
proceeds from issuance of class a common stock in follow-on offering							0	0	0	115,000,000	-1,000
cash, cash equivalents and restricted cash, beginning of year
cash, cash equivalents and restricted cash, end of year
cash paid for interest							853,000	863,000			559,000	119,000
issuance of class a common stock in payment of licensing fees
issuance of class a common stock for licensing payment
net decrease in cash and cash equivalents and restricted cash								-6,448,000
issuance of class a common stock in payment of accrued development milestone
payment for mau868 asset purchase
restructuring payments															-124,000	-125,000	-160,000	-590,000
gain on sale of pnai technology															0	0
proceeds from sale of pnai technology															0	0
proceeds from issuance of class a common stock upon initial public offering, net of underwriting discounts and commissions															0	0
payment of offering costs related to initial public offering															0	0
reclassification of redeemable convertible preferred stock into common stock upon initial public offering																0
non-marketable equity securities received as partial proceeds from sale of pnai technology																0
lease assignment																0
liability assumed in connection with mau868 asset purchase
payment of costs related to initial public offering
reclassification of redeemable convertible preferred stock into class a common stock and class b common stock upon initial public offering
prepaid expenses and other current assets														-3,942,000
proceeds from issuance of class a common stock offering, net of underwriting discounts and commissions														86,130,000
payment of costs related to underwritten follow-on offering														-6,096,000
payment of deferred offering costs																		-369,000
payment on capital lease obligations																		-1,000
deferred offering costs included in accounts payable																		729,000
deferred offering costs included in accrued and other current liabilities																		195,000
impairment loss on property and equipment and intangible asset
issuance of series c redeemable convertible preferred stock for license
non-cash interest expense on convertible notes
issuance costs for convertible notes
gain on issuance of convertible notes
change in fair value of convertible notes
other liabilities
proceeds from the sale of property and equipment
proceeds from exercise of stock options															0	0	208,000	342,000
proceeds from issuance of series c redeemable convertible preferred stock
payment of issuance costs related to issuance of redeemable convertible preferred stock
proceeds from issuance of convertible notes
payment of issuance costs related to convertible notes
payment issuance costs related to convertible promissory notes

We provide you with 20 years of cash flow statements for Vera Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Vera Therapeutics stock. Explore the full financial landscape of Vera Therapeutics stock with our expertly curated income statements.

The information provided in this report about Vera Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.